ArticleActa pharmacologica Sinica2024

A novel selective ERK1/2 inhibitor, Laxiflorin B, targets EGFR mutation subtypes in non-small-cell lung cancer.

Cheng-Yao Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.